Insider Sell Alert: Conmed Corp's President AS and AET Peters Stanley W III Offloads Shares
ConMed(CNMD.US) Officer Sells US$252.83K in Common Stocks
$ConMed(CNMD.US)$ Officer Peters Stanley W III sold 2,300 shares of Common Stocks on Dec 4, 2023 at an average price of $109.9276 for a total value of $252.83K.Source: Announcement What is statement o
Conmed Insider Sold Shares Worth $252,833, According to a Recent SEC Filing
Stanley W Peters III, President, Advanced Surgical and Advanced Endoscopic Technologies, on December 04, 2023, sold 2,300 shares in Conmed (CNMD) for $252,833. Following the Form 4 filing with the SEC
4K Medical Imaging Market, Size & Forecast 2024-2030, Featuring Profiles of Stryker, Zimmer Biomet Holdings, Smith & Nephew, Conmed, Medtronic, Sony, Fujifim and Hitachi
The "4K Medical Imaging Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has...
ConMed To Go Ex-Dividend On December 15th, 2023 With 0.2 USD Dividend Per Share
December 6th - $ConMed(CNMD.US)$ is trading ex-dividend on December 15th, 2023. Shareholders of record on December 18th, 2023 will receive 0.2 USD dividend per share on January 5th, 2024. The ex-d
CONMED Corporation Announces Quarterly Cash Dividend
CONMED Corporation (NYSE:CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on December 4, 2023, payable on January 5, 2024, to all shareholders of record as of
Are Investors Undervaluing CONMED Corporation (NYSE:CNMD) By 45%?
Key Insights CONMED's estimated fair value is US$194 based on 2 Stage Free Cash Flow to Equity CONMED's US$106 share price signals that it might be 45% undervalued The US$123 analyst price target
Conmed (CNMD) Up 14.3% Since Last Earnings Report: Can It Continue?
Is There An Opportunity With CONMED Corporation's (NYSE:CNMD) 44% Undervaluation?
Here's Why You Should Retain CONMED (CNMD) Stock for Now
CONMED Corporation to Participate in a Fireside Chat at the Piper Sandler Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice Presi
Global Uterine Manipulation Devices Market Trends Analysis Report 2023 - 2030, Featuring Profiles of Conkin Surgical Instruments, CONMED, CooperSurgical, LSI Solutions and More
The "Uterine Manipulation Devices Market Size, Share & Trends Analysis Report By Application (Total Laparoscopy Hysterectomy, Laparoscopic...
ConMed(CNMD.US) Officer Sells US$122.87K in Common Stocks
$ConMed(CNMD.US)$ Officer Peters Stanley W III sold 1,200 shares of Common Stocks on Nov 7, 2023 at an average price of $102.395 for a total value of $122.87K.Source: Announcement What is statement of
Conmed Insider Sold Shares Worth $122,874, According to a Recent SEC Filing
Stanley W Peters III, President, Advanced Surgical and Advanced Endoscopic Technologies, on November 07, 2023, sold 1,200 shares in Conmed (CNMD) for $122,874. Following the Form 4 filing with the SEC
Is It Time To Consider Buying CONMED Corporation (NYSE:CNMD)?
CONMED Corporation (NYSE:CNMD), is not the largest company out there, but it saw significant share price movement during recent months on the NYSE, rising to highs of US$123 and falling to the lo
CONMED Corporation to Participate in Fireside Chats at Two Investor Conferences on November 14-15
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will participate in fireside chats at the following two investor conferences in November:Conference: Stifel Health
Analysts Are Bullish on These Healthcare Stocks: Conmed (CNMD), Resmed (RMD)
CONMED Corporation (NYSE:CNMD) Q3 2023 Earnings Call Transcript
Piper Sandler Adjusts Price Target on CONMED to $130 From $145, Maintains Overweight Rating
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here:
Piper Sandler Maintains Overweight on Conmed, Lowers Price Target to $130
Piper Sandler analyst Matt O'Brien maintains Conmed with a Overweight and lowers the price target from $145 to $130.